Clinical trials recruiting for Ovarian cancer
118
Recruiting trials
47
US states with sites
33
Countries
10%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 41 |
| California | 37 |
| New York | 29 |
| Florida | 27 |
| Ohio | 21 |
| Massachusetts | 19 |
| Tennessee | 19 |
| Virginia | 18 |
| Pennsylvania | 17 |
| Illinois | 15 |
| Michigan | 13 |
| Arizona | 12 |
Top cities
Houston, Texas 30New York, New York 20Los Angeles, California 19Nashville, Tennessee 19Boston, Massachusetts 17Fairfax, Virginia 15San Antonio, Texas 13Philadelphia, Pennsylvania 12Dallas, Texas 11Duarte, California 10
Self-screener
Recruiting trials
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- A Beta-only IL-2 ImmunoTherapY Study
- A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer
- A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
- A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
- A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
- A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
- A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks
- A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
- A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- A Study of MGC026 in Participants With Advanced Solid Tumors
- A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
- A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
- A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
- A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- AOH1996 for the Treatment of Refractory Solid Tumors
- APG-2449 in Patients With Advanced Solid Tumors
- Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
- Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
- Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
- Avera Cancer Sequencing and Analytics Protocol (ASAP)
- BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
- Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
- CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
- Cancer Loyalty Card Study 2 (CLOCS-2)
- Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors
- Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
- Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
- Comprehensive Outcomes for After Cancer Health
- Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique)
- DESTINY-PANTUMOUR04
- Deciphering Mechanisms Underlying Cancer Immunogenicity
- Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
- Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
- Distance-Based Exercise to Preserve Function and Prevent Disability
- Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
- Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
- EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
- EXoPERT EMERALD Clinical Study
- Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
- Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers
- Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
- Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology
- FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
- FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine
- Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
- IDOV-Immune for Advanced Solid Tumors
- INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)
- Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
- Integrated Cancer Repository for Cancer Research
- Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)
- LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
- Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Liquid Biopsy Evaluation and Repository Development at Princess Margaret
- Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing
- Measuring Oncological Value of Exercise and Statin
- NYSCF Scientific Discovery Biobank
- Navigation Intervention for Adolescent and Young Adult Cancer Survivors
- Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
- PITCHER (Peritoneal Carcinomatosis Heterogeneity)
- Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy
- Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host
- Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
- Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
- Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
- Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
- Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
- Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
- Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
- Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
- SL-28 for Advanced Solid Tumours
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
- Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Sample Collection for Ongoing Research and Product Evaluation Study
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Related conditions
Trials recruiting for Ovarian cancer often also study these conditions. Each links to its own recruiting-trial list.
Breast cancer 2239Lung cancer 2180Colorectal cancer 1359Pancreatic cancer 870Prostate cancer 1234Endometrial cancer 68Cervical cancer 71Melanoma 487Gastric cancer 91Non-small cell lung cancer 507
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Ovarian cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.